Long-Term Follow-Up Study of Unilateral Microtia Patients Implanted With AUR-201

Key facts

Sponsor

Auregen Biotherapeutics, SA

Principal Investigator

Thomas Romo, III, MD, FACS

Romo Plastic Surgery

Intervention

AUR-201(combination_product)

Enrollment

1 target

Eligibility

8-29 years · All sexes

Timeline

2024 – 2025

Study locations (1)

• Romo Plastic Surgery, New York, New York, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Microtia

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT06087874
  Preventive Effect of Perinatal Oral Probiotic Supplementation (POPS) on Neonatal Jaundice
  Chinese University of Hong Kong
• ACTIVE NOT RECRUITINGNCT06289283
  Microbiota in Urine and Urothelium Can be a Factor for Induction of Urinary Bladder Cancer. The Study Will Examine Urine and Bladder Cancer Tissues From Male Patients and Urine of Controls Using Whole Genomic Sequencing Techniques and 16S rRNA. The Aim is to Elucidate Role of Microbiota in Bladder
  Theodor Bilharz Research Institute
• RECRUITINGPHASE2NCT05288790
  Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
  Vanderbilt University Medical Center

See all trials for Microtia →